Xu L - Search Results

1

Identification and validation of novel small molecule disruptors of HuR-mRNA interaction.

Wu X, Lan L, Wilson DM, Marquez RT, Tsao WC, Gao P, Roy A, Turner BA, McDonald P, Tunge JA, Rogers SA, Dixon DA, Aubé J, Xu L. Wu X, et al. Among authors: xu l. ACS Chem Biol. 2015 Jun 19;10(6):1476-84. doi: 10.1021/cb500851u. Epub 2015 Mar 17. ACS Chem Biol. 2015. PMID: 25750985 Free PMC article.

2

Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.

Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, Ji M, Pienta K, Lawrence T, Xu L. Meng Y, et al. Among authors: xu l. Mol Cancer Ther. 2008 Jul;7(7):2192-202. doi: 10.1158/1535-7163.MCT-08-0333. Mol Cancer Ther. 2008. PMID: 18645028 Free PMC article.

3

Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives.

Wu X, Li M, Tang W, Zheng Y, Lian J, Xu L, Ji M. Wu X, et al. Among authors: xu l. Chem Biol Drug Des. 2011 Dec;78(6):932-40. doi: 10.1111/j.1747-0285.2011.01234.x. Epub 2011 Oct 24. Chem Biol Drug Des. 2011. PMID: 21895983 Free PMC article.

4

Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch.

Marquez RT, Xu L. Marquez RT, et al. Among authors: xu l. Am J Cancer Res. 2012;2(2):214-21. Epub 2012 Feb 15. Am J Cancer Res. 2012. PMID: 22485198 Free PMC article.

5

HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s.

Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS, Xu L. Li L, et al. Among authors: xu l. Clin Cancer Res. 2013 Dec 15;19(24):6703-15. doi: 10.1158/1078-0432.CCR-13-0621. Epub 2013 Oct 16. Clin Cancer Res. 2013. PMID: 24132924 Free PMC article.

6

A PEG-Fmoc conjugate as a nanocarrier for paclitaxel.

Zhang P, Huang Y, Liu H, Marquez RT, Lu J, Zhao W, Zhang X, Gao X, Li J, Venkataramanan R, Xu L, Li S. Zhang P, et al. Among authors: xu l. Biomaterials. 2014 Aug;35(25):7146-56. doi: 10.1016/j.biomaterials.2014.04.108. Epub 2014 May 22. Biomaterials. 2014. PMID: 24856103 Free PMC article.

7

Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.

Lu J, Zhao W, Huang Y, Liu H, Marquez R, Gibbs RB, Li J, Venkataramanan R, Xu L, Li S, Li S. Lu J, et al. Among authors: xu l. Mol Pharm. 2014 Nov 3;11(11):4164-78. doi: 10.1021/mp500389v. Epub 2014 Sep 29. Mol Pharm. 2014. PMID: 25265550 Free PMC article.

8

Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif.

Zhang X, Huang Y, Zhao W, Liu H, Marquez R, Lu J, Zhang P, Zhang Y, Li J, Gao X, Venkataramanan R, Xu L, Li S. Zhang X, et al. Among authors: xu l. Biomacromolecules. 2014 Nov 10;15(11):4326-35. doi: 10.1021/bm501339j. Epub 2014 Oct 28. Biomacromolecules. 2014. PMID: 25325795 Free PMC article.

9

An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.

Lu J, Zhao W, Liu H, Marquez R, Huang Y, Zhang Y, Li J, Xie W, Venkataramanan R, Xu L, Li S. Lu J, et al. Among authors: xu l. J Control Release. 2014 Dec 28;196:272-86. doi: 10.1016/j.jconrel.2014.10.016. Epub 2014 Oct 24. J Control Release. 2014. PMID: 25456831 Free PMC article.

10

Overexpression of 17β-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death.

Carlson EA, Marquez RT, Du F, Wang Y, Xu L, Yan SS. Carlson EA, et al. Among authors: xu l. BMC Cancer. 2015 Mar 22;15:166. doi: 10.1186/s12885-015-1173-5. BMC Cancer. 2015. PMID: 25879199 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41,761 results

Search Page

Filters